https://www.selleckchem.com/pr....oducts/itacitinib-in
The estimated difference between control and metastasectomy patients was -0.23 (95% CI -0.113, 0.066) for the composite 0 to 1 index scale based on the descriptive system and 0.123 (95% CI -7.24, 7.49) for the 0 to 100 VAS scale. Following lung metastasectomy for CRC, no benefit was demonstrated for health utility, which alongside a lack of a survival or quality of life benefit calls into question the widespread use of the procedure. Following lung metastasectomy for CRC, no benefit was demonstrated for health utility, whic
Like
Comment
Share
